New drug aims to quiet chronic hives
NCT ID NCT07717905
First seen Jul 21, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests an experimental drug called BBT001 in adults with chronic spontaneous urticaria, a condition causing frequent hives without a clear trigger. Participants receive multiple doses of BBT001 or a placebo to see if it is safe and helps control symptoms. The trial focuses on safety, how the drug moves through the body, and its potential to reduce hive activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called BBT001
- What this could lead to
- If successful, BBT001 could offer a new treatment option for people with chronic hives that are not controlled by standard antihistamines.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dermatology Hospital of Southern Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510440, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hangzhou Third People's Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jingzhou Central Hospital
NOT_YET_RECRUITINGJinzhou, Hubei, 434020, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital, Beijing
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
The First Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510260, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Wannan Medical College
NOT_YET_RECRUITINGWuhu, Anhui, 241001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, 710114, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Hospital of Shanxi Medical University
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wuxi Second People's Hospital,
NOT_YET_RECRUITINGWuxi, Jiangsu, 214002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise
- New drug HRS-3095 aims to soothe stubborn hives
- New shot could tame stubborn hives for good
- New hope for teens with stubborn hives: drug trial launches